Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Priority to CO10098050ApriorityCriticalpatent/CO6290680A2/en
Publication of CO6290680A2publicationCriticalpatent/CO6290680A2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente invención se refiere a composiciones de (4,4-diimidazolil)bifenilos y a métodos para el tratamiento del virus de la hepatitis C (VHC). También se describen composiciones farmacéuticas que contienen estos compuestos y métodos para el uso de estos compuestos en el tratamiento de infección por VHC.The present invention relates to compositions of (4,4-diimidazolyl) biphenyls and methods for the treatment of hepatitis C virus (HCV). Pharmaceutical compositions containing these compounds and methods for the use of these compounds in the treatment of HCV infection are also described.
CO10098050A2010-08-102010-08-10
HEPATITIS C VIRUS INHIBITORS
CO6290680A2
(en)
Compounds derived from haloalkyl heteroaryl benzamides; pharmaceutical composition use of the composition in the treatment of a viral infection, such as hepatitis b and c virus.
Compounds derived from biphenyl-pyrrolidinyl-imidazole; pharmaceutical composition comprising them; its use in the treatment of an hcv viral infection.
Benzimidazole-imidazole derivative compounds, hepatitis c virus (hcv) inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; use in the prevention or treatment of hcv infection.
Compounds derived from 1,3,4,8-tetrahydro-2h-pyrido [1,2-a] pyrazine; pharmaceutical composition that includes them; pharmaceutical kit; and its use as hiv integrase inhibitors for the treatment of an infectious hiv disease.
Compounds derived from condensed heterocycles, hepatitis c virus inhibitors; pharmaceutical composition that contains them; and its use for the treatment of hepatitis c virus infection.